• +1-646-491-9876
    • +91-20-67278686

    Search

    Smallpox - Pipeline Review, H1 2017

    Smallpox - Pipeline Review, H1 2017

    • Report Code ID: RW0001689456
    • Category Healthcare
    • No. of Pages 74
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Smallpox - Pipeline Review, H1 2017, provides an overview of the Smallpox (Infectious Disease) pipeline landscape.

    Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Smallpox - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Smallpox (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Smallpox (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 3, 8 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

    Smallpox (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Smallpox (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Smallpox - Overview
    Smallpox - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Smallpox - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Smallpox - Companies Involved in Therapeutics Development
    Bavarian Nordic A/S
    BioFactura Inc
    CEL-SCI Corp
    Chimerix Inc
    CJ HealthCare Corp
    EpiVax Inc
    N & N Pharmaceuticals Inc
    SIGA Technologies Inc
    Takeda Pharmaceutical Company Ltd
    Tonix Pharmaceuticals Holding Corp
    Smallpox - Drug Profiles
    (plague + small pox) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    24a - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    brincidofovir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CEL-1000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CJ-40011 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies for Infectious Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for Smallpox - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NN-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PL-801 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SCV-305 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    smallpox vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    smallpox vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tecovirimat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TNX-801 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VIR-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Smallpox - Dormant Projects
    Smallpox - Discontinued Products
    Smallpox - Product Development Milestones
    Featured News & Press Releases
    Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-801 at 9th Annual Biotech Showcase Conference
    Jan 06, 2017: Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects
    Nov 23, 2016: Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE Smallpox Vaccine
    Sep 21, 2016: SIGA Announces Bankruptcy Court Approval of Transaction Under Which SIGA Will Pay PharmAthene Claim in Full
    Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government
    Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral
    Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
    Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene
    Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox
    Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
    Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million
    May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine
    Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery
    Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million
    Dec 23, 2014: Chimerix Provides Recap of 2014 Events
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Smallpox, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Smallpox - Pipeline by Bavarian Nordic A/S, H1 2017
    Smallpox - Pipeline by BioFactura Inc, H1 2017
    Smallpox - Pipeline by CEL-SCI Corp, H1 2017
    Smallpox - Pipeline by Chimerix Inc, H1 2017
    Smallpox - Pipeline by CJ HealthCare Corp, H1 2017
    Smallpox - Pipeline by EpiVax Inc, H1 2017
    Smallpox - Pipeline by N & N Pharmaceuticals Inc, H1 2017
    Smallpox - Pipeline by SIGA Technologies Inc, H1 2017
    Smallpox - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017
    Smallpox - Dormant Projects, H1 2017
    Smallpox - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Smallpox - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Smallpox, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Bavarian Nordic A/S
    BioFactura Inc
    CEL-SCI Corp
    Chimerix Inc
    CJ HealthCare Corp
    EpiVax Inc
    N & N Pharmaceuticals Inc
    SIGA Technologies Inc
    Takeda Pharmaceutical Company Ltd
    Tonix Pharmaceuticals Holding Corp

    Request for Sample

    Report Url http://www.reportsweb.com//smallpox-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//smallpox-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//smallpox-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments